Koo HM - Search Results

1

Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer.

Melnik MK, Webb CP, Richardson PJ, Luttenton CR, Campbell AD, Monroe TJ, O'Rourke TJ, Yost KJ, Szczepanek CM, Bassett MR, Truszkowski KJ, Stein P, Van Brocklin MW, Davis AT, Bedolla G, Vande Woude GF, Koo HM. Melnik MK, et al. Among authors: koo hm. Mol Cancer Ther. 2010 Aug;9(8):2423-9. doi: 10.1158/1535-7163.MCT-09-0854. Epub 2010 Aug 3. Mol Cancer Ther. 2010. PMID: 20682649 Clinical Trial.

2

Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad.

Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM. Eisenmann KM, et al. Among authors: koo hm. Cancer Res. 2003 Dec 1;63(23):8330-7. Cancer Res. 2003. PMID: 14678993

3

Reanalysis of cancer drugs: old drugs, new tricks.

Vande Woude GF, Kelloff GJ, Ruddon RW, Koo HM, Sigman CC, Barrett JC, Day RW, Dicker AP, Kerbel RS, Parkinson DR, Slichenmyer WJ. Vande Woude GF, et al. Among authors: koo hm. Clin Cancer Res. 2004 Jun 1;10(11):3897-907. doi: 10.1158/1078-0432.CCR-03-0786. Clin Cancer Res. 2004. PMID: 15173099 Review. No abstract available.

4

Ras oncogene-induced sensitization to 1-beta-D-arabinofuranosylcytosine.

Koo HM, McWilliams MJ, Alvord WG, Vande Woude GF. Koo HM, et al. Cancer Res. 1999 Dec 15;59(24):6057-62. Cancer Res. 1999. PMID: 10626790

5

Re: The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis.

Koo HM, Vande Woude GF. Koo HM, et al. J Natl Cancer Inst. 1999 Nov 17;91(22):1969. doi: 10.1093/jnci/91.22.1969. J Natl Cancer Inst. 1999. PMID: 10564683 No abstract available.

6

Novel protein targeted therapy of metastatic melanoma.

Frankel AE, Koo HM, Leppla SH, Duesbery NS, Vande Woude GF. Frankel AE, et al. Among authors: koo hm. Curr Pharm Des. 2003;9(25):2060-6. doi: 10.2174/1381612033454162. Curr Pharm Des. 2003. PMID: 14552326 Review.

7

Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways.

Duesbery NS, Resau J, Webb CP, Koochekpour S, Koo HM, Leppla SH, Vande Woude GF. Duesbery NS, et al. Among authors: koo hm. Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4089-94. doi: 10.1073/pnas.061031898. Epub 2001 Mar 20. Proc Natl Acad Sci U S A. 2001. PMID: 11259649 Free PMC article.

8

Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.

Koo HM, Monks A, Mikheev A, Rubinstein LV, Gray-Goodrich M, McWilliams MJ, Alvord WG, Oie HK, Gazdar AF, Paull KD, Zarbl H, Vande Woude GF. Koo HM, et al. Cancer Res. 1996 Nov 15;56(22):5211-6. Cancer Res. 1996. PMID: 8912859

9

Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase.

Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Vande Woude GF. Koo HM, et al. Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3052-7. doi: 10.1073/pnas.052707699. Epub 2002 Feb 26. Proc Natl Acad Sci U S A. 2002. PMID: 11867750 Free PMC article.

10

Radioimmunoscintigraphy of human met-expressing tumor xenografts using met3, a new monoclonal antibody.

Hay RV, Cao B, Skinner RS, Wang LM, Su Y, Resau JH, Knudsen BS, Gustafson MF, Koo HM, Vande Woude GF, Gross MD. Hay RV, et al. Among authors: koo hm. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3839S-44S. Clin Cancer Res. 2003. PMID: 14506181

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters